Circulation
-
Randomized Controlled Trial
Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study.
Pulmonary hypertension caused by systolic left ventricular dysfunction is associated with significant morbidity and mortality; however, no treatment is approved for this indication. We hypothesized that riociguat, a novel soluble guanylate cyclase stimulator, would have beneficial hemodynamic effects in patients with pulmonary hypertension caused by systolic left ventricular dysfunction. ⋯ URL: http://www.clinicaltrials.gov. Unique identifier: NCT01065454.
-
Randomized Controlled Trial Multicenter Study Comparative Study
Preliminary experience with social media for community consultation and public disclosure in exception from informed consent trials.